Clinical Trial News and Research

RSS

CT angiography provides accurate assessment of arterial plaque in diabetic patients

Imaging of the coronary arteries with computed tomography (CT) angiography provides an accurate assessment of arterial plaque and could have a dramatic impact on the management of diabetic patients who face a high risk of heart attacks and other cardiovascular events, according to a new multicenter study published online in the journal Radiology.

22 Apr 2014

Shiseido Cell-Processing and Expansion Center to be opened in Kobe, Japan

Shiseido Co., Ltd. announces plans to open the Shiseido Cell-Processing and Expansion Center (SPEC) on May 1, 2014. The center, located in the in the Kobe Biomedical Innovation Cluster in Kobe, Japan, will centralize research and development on hair regenerative medicine with an aim toward commercialization.

22 Apr 2014

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

Cubist submits ceftolozane/tazobactam NDA for treatment of cUTI and cIAI

Cubist Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for approval of its investigational antibiotic ceftolozane/tazobactam for the treatment of Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI).

21 Apr 2014

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society.

21 Apr 2014

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).

21 Apr 2014

Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).

21 Apr 2014

Blog explains why NeutroPhase can play important role in treating 'flesh-eating' infections

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that WoundSource™ has highlighted NovaBay's NeutroPhase wound cleanser in a recent blog posting. The blog explains why NeutroPhase can play an important role in treating life-threatening necrotizing fasciitis, or 'flesh-eating' infections.

21 Apr 2014

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML).

21 Apr 2014

Evidence-based interventions provide promising strategies for reducing racial, ethnic health disparities

Evidence-based interventions at the local and national levels provide promising strategies for reducing racial and ethnic health disparities related to HIV infection rates, immunization coverage, motor vehicle injuries and deaths, and smoking, according to a new report by the CDC's Office of Minority Health and Health Equity.

21 Apr 2014

IV-administered ketamine effective in patients with chronic PTSD

For the first time, evidence that a single dose of IV-administered ketamine was associated with the rapid reduction of symptoms of post-traumatic stress disorder in patients with chronic PTSD was demonstrated in a proof-of-concept, randomized, double blind crossover study, undertaken by researchers at the Icahn School of Medicine at Mount Sinai in New York City. These findings, according to Mount Sinai researchers, could be the first step toward developing new interventions for PTSD.

21 Apr 2014

Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered a molecule, or biomarker, called CD61 on the surface of drug-resistant tumors that appears responsible for inducing tumor metastasis by enhancing the stem cell-like properties of cancer cells.

21 Apr 2014

Researchers devise new approach to treatment of Alzheimer's disease

A team of researchers from Columbia University Medical Center, Weill Cornell Medical College, and Brandeis University has devised a wholly new approach to the treatment of Alzheimer's disease involving the so-called retromer protein complex. Retromer plays a vital role in neurons, steering amyloid precursor protein (APP) away from a region of the cell where APP is cleaved, creating the potentially toxic byproduct amyloid-beta, which is thought to contribute to the development of Alzheimer's.

21 Apr 2014

Pfizer to highlight Blue Button initiative at DIA 2014 Annual Meeting in San Diego

Craig Lipset, head of clinical innovation at Pfizer Inc., will join advocates of patient data accessibility to highlight the Blue Button initiative at the DIA 2014 50th Annual Meeting in San Diego.

18 Apr 2014

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the signing of a discovery and co-development agreement with Southern Research Institute, a not-for-profit 501(c)(3) scientific research organization founded in 1941.

18 Apr 2014

Scientist receives $1.8M defense grant from Kessler Foundation for spinal cord injury research

Kessler Foundation has been named awardee of a three-year grant for $1.8 million from the Department of Defense Spinal Cord Injury Research Program. Gail Forrest, PT, PhD, is principal investigator for the randomized, double-blinded, controlled, multi-site clinical trial, which will test strategies to improve bone and muscle strength after spinal cord injury. Dr. Forrest is assistant director of Human Performance & Engineering Research at Kessler Foundation.

18 Apr 2014

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial.

From Medtronic 18 Apr 2014

Clinical Trial News and Research

CT angiography provides accurate assessment of arterial plaque in diabetic patients

Shiseido Cell-Processing and Expansion Center to be opened in Kobe, Japan

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Cubist submits ceftolozane/tazobactam NDA for treatment of cUTI and cIAI

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy

Blog explains why NeutroPhase can play important role in treating 'flesh-eating' infections

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Evidence-based interventions provide promising strategies for reducing racial, ethnic health disparities

IV-administered ketamine effective in patients with chronic PTSD

Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Researchers devise new approach to treatment of Alzheimer's disease

Pfizer to highlight Blue Button initiative at DIA 2014 Annual Meeting in San Diego

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Scientist receives $1.8M defense grant from Kessler Foundation for spinal cord injury research

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

Agios begins AG-348 Phase 1 study to treat PK deficiency

Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery